Personalis Inc. (US71535D1063.SG)

1mon ago, source: Yahoo Finance

Personalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Call Transcript February 28, 2024 Personalis, Inc. misses on earnings expectations. Reported EPS is $-0.54 EPS, expectations were $-0.53.

Buy Rating Affirmed for Personalis, Inc. on Strong Growth Prospects and Innovative Cancer Assays

9d ago, source:

Analyst Michael Matson of Needham maintained a Buy rating on Personalis (PSNL – Research Report), retaining the price target of $3.50.

Personalis: Q4 Earnings Snapshot

1mon ago, source: Times Union

FREMONT, Calif. (AP) — FREMONT, Calif. (AP) — Personalis Inc. (PSNL) on Wednesday reported a loss of $26.6 million in its fourth quarter. On a per-share basis, the Fremont, California-based ...

Personalis Inc.

23d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

25d ago, source: Stockhouse

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive ...

Cathie Wood's Ark Laps Up $3.3M Worth Of Tesla As Stock Falls For 3rd Straight Session, Sheds Shares Of This Sports Betting Company

3d ago, source:

Tesla found favor with bullish fund manager Cathie Wood, as her firm lapped up Tesla shares following its 10% slide over ...

Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference

23d ago, source: ADVFN

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on ...

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

25d ago, source: Morningstar

Blood-based assay uses personalized tumor-informed approach designed to detect cancer recurrence early with an ultra-sensitive approach Personalis, Inc. (Nasdaq: PSNL), a leader in advanced ...

Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference

23d ago, source: Yahoo Finance

FREMONT, Calif., March 28, 2024--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23 rd Annual ...